Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?

Simply Wall St.07-07

On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649670565?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-07-07 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649670565","market":"hk","top_or_hot":-1,"title":"Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?","media":"Simply Wall St.","content":"<div>\n<p>On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-07 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","article_id":"2649670565","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649670565","pubTimestamp":1783384360,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap Growth Benchmark Index.\nThis broad index removal can alter how index-linked and institutional investors hold or trade Adaptive Biotechnologies, potentially reshaping the stock’s investor base and liquidity profile.\nWe’ll now examine how Adaptive Biotechnologies’ removal from multiple Russell...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","HELX":"Franklin Genomic Advancements ETF","ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"罗素指数的删除是否会重塑适应性生物技术（ADPT）的牛市？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HELX":0.6,"ADPT":1.5},"content_text":"On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap Growth Benchmark Index. This broad index removal can alter how index-linked and institutional investors hold or trade Adaptive Biotechnologies, potentially reshaping the stock’s investor base and liquidity profile. We’ll now examine how Adaptive Biotechnologies’ removal from multiple Russell indices may influence its existing investment narrative and future risk profile. We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementAdaptive Biotechnologies Investment Narrative RecapTo own Adaptive Biotechnologies, you need to believe its MRD platform can justify ongoing losses while Immune Medicine either matures or is successfully separated. The broad Russell index removals do not directly change these core fundamentals in the near term, but they can add some short term trading volatility and may compound the key risk that continued unprofitability could eventually force less favorable funding or deeper cost cuts. The most relevant recent development is Adaptive’s June 2026 decision to explore separating its MRD and Immune Medicine businesses. That review, alongside raised 2026 MRD revenue guidance to US$260 million to US$270 million, sits at the heart of the current catalyst: MRD’s path toward scale and improved cash burn versus the risk that Immune Medicine’s uncertain economics and any future transaction terms could weigh on shareholder outcomes. Yet beneath the index changes, one risk investors should be watching closely is whether ongoing losses and cash needs could eventually force... Read the full narrative on Adaptive Biotechnologies (it's free!)Adaptive Biotechnologies' narrative projects $451.6 million revenue and $70.4 million earnings by 2029. This requires 15.2% yearly revenue growth and an earnings increase of about $120 million from -$49.7 million today.Uncover how Adaptive Biotechnologies' forecasts yield a $20.14 fair value, a 6% downside to its current price.Exploring Other PerspectivesADPT 1-Year Stock Price Chart While consensus highlights funding risk and partner dependence, the most optimistic analysts were assuming revenue could reach about US$474 million by 2029, so this broad index removal could prompt some of those views to be revisited as opinions adjust around how quickly Adaptive can really grow into that profile.Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth 6% less than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.Ready For A Different Approach?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Find 41 companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649670565","isCrawlerRequest":true}